Ensuring Leadership Continuity—The Coleman Health Services Case Study is starting in

Youth Taking GLP-1 Medications For Obesity Have Less Suicidal Ideation

Youth prescribed a glucagon-like peptide 1 receptor agonist (GLP1R) medication for obesity had a 33% reduced risk for suicidal ideation or attempts over 12 months of follow-up. A total of 1.45% of those with a GLP1R prescription had suicidal ideation or attempts, compared to 2.26% of those without a GLP1R prescription.

Those with a GLP1R prescription had a higher rate of gastrointestinal (GI) symptoms over the 12-month follow-up period. A total of 6.9% of those on a GLP1R prescription had GI symptoms, compared to 5.4% of those without a GLP1R prescription. Despite . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.